期刊文献+

麝香保心丸联合硝酸异山梨醇酯片治疗冠心病心绞痛的疗效观察 被引量:3

The Effects of Musk Fills with Combination of Iscaorbide Dinitratr Tablet in Treatment of Angina Pectoris
下载PDF
导出
摘要 目的探讨麝香保心丸联合硝酸异山梨醇酯片(消心痛)治疗冠心病心绞痛的疗效及其对血脂的影响。方法选取冠心病心绞痛患者100例,随机分为两组,治疗组口服麝香保心丸,每次2粒,每日3次,消心痛每次5 mg,每日3次,对照组50例单用硝酸异山梨醇酯片(消心痛)治疗。每次10 mg,每日3次。两组疗程均为2月。观察临床疗效、心电图、治疗前后血脂变化情况。结果治疗组临床症状改善及心电图改善率、血脂改善情况明显优于对照组(P<0.05)。且没有明显的毒副作用,值得大力推广。结论麝香保心丸联合消心痛是一种安全、有效的治疗冠心病心绞痛的药物。联合应用比单用消心痛更有效。 Objective The aim of this study was to observe the therapeutic effects and lowering blood lipid effects of heart-protecting Musk fills(HMF) with combination of iscaorbide dinitratr(cedocard) in treating the coronary-angina pectoris.Methods We observed 100 cases that suffered from coronary heart disease who were divided into two groups randomly: treatment group(50 cases) were treated with HMF(two pills,third daily by oral) and isosorbide dinitratr(5 mg,third daily by oral),in control group(50 cases) were treated in isosorbide dinitratr(10 mg,third daily by oral).All cases with 2 months course of treatment.And observe the clinical therapeutic effects,electrocardiogram,blood-fat changing.Results HMF could significantly improve the clinical symptoms,enhance the improvement rate of electrocardiogram and reduce the blood-fat level compare to the control group(P〈0.05).Moreover,HME was no significant toxic and side reactions,therefore,to be worth using.Conclusions Musk fills(HMF) is a safety and effective drug for the treatment of coronary angina pectoris,and combination with iscaorbide dinitratr more effective than iscaorbide dinitratr single.
出处 《辽宁医学院学报》 CAS 2010年第3期212-213,230,共3页 Journal of Liaoning Medical University (LNMU) Bimonthly
关键词 麝香保心丸 硝酸异山梨醇酯片(消心痛) 冠心病心绞痛 heart-protecting musk fills iscaorbide dinitratr coronary angina pectoris
  • 相关文献

参考文献6

二级参考文献25

  • 1贾公孚.药物联用禁忌手册,第1版[M].北京:中国协和医科大学出版社,2000,8.657.
  • 2Luc G, Bard J M, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: The PRIME Study. Atherosclerosis, 2001,163(2):377-384.
  • 3Seman L G, Deluca C, Jenner J L,et al. Lipoprotein (a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem, 1999,45(7):1039-1046.
  • 4Lundstam U, Herlitz J, Karlsson T, et al. Serum lipids, lipoprtein (a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease. J Intern Med, 2002,251(2):111-118.
  • 5Marcovina S M, Hegele R A, Koschinsky M L. Lipoprotein (a) and coronary heart disease risk. Curr Cardiol Rep,1999,1(2):105-111.
  • 6Angles C E. Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process. Braz J Med Biol Res,1997,30(11):1271-1280.
  • 7Maeda S, Abe A, Seishima M, et al. Transient change of serum lipoprotein (a) as an acute phase protein. Atherosclerosis, 1989,78(1):145-150.
  • 8Greory Y H, Gordon D L. Fibrin D-dimer: A useful marker of thrombogenesis? Clini Sci,1995(89):205-214.
  • 9黄成君,李强忠,矫丽华,王克美.从甲襞微循环的改变看麝香保心丸对冠心病的疗效[J].上海医药,1997(5):13-14. 被引量:5
  • 10严序炳,高敏,严小娟,王颖,王令嘉.麝香保心丸与消心痛在防治冠心病中的对比研究[J].上海医药,1997(5):23-26. 被引量:6

共引文献754

同被引文献14

引证文献3

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部